Chemical Namevoxelotor
Dosage FormTablet (oral; 500 mg)
Drug ClassInhibitors
CompanyGlobal Blood Therapeutics
Approval Year2019


  • Oxbryta is indicated for the treatment of sickle cell disease in adults and pediatric patients 12 years of age and older.
Last updated on 6/11/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Oxbryta (voxelotor) Prescribing Information2019Global Blood Therapeutics